therapeutic_2

Immunostimulatory ADCs (iADCs), also known as immune-stimulating antibody conjugates (iSACs), arean advanced form of targeted cancer therapy. They not only activate innate immunity but also stimulate adaptive immunity, providing a dual therapeutic effect to eliminate tumor cells. They combine

The approval of Eli Lilly’s Kisunla (donanemab-azbt), a humanized IgG1 monoclonal antibody, is just one of the major advancements in the treatment of Alzheimer's disease (AD)! This drug is now available in the US for adults with early symptomatic AD, including those with mild cognitive impairment (MCI) and mild dementia stage of AD with amyloid pathology.

Blood disorders, including anemias, coagulopathies, leukemias, lymphomas, and thrombocytopenias, disrupt the normal functioning of blood components. Antibody therapeutics, such as monoclonal antibodies (mAbs), have transformed treatment approaches by offering targeted, high-specificity interventions.

Camelids provide the origin of VHH antibodies. Biointron highlights their unique biology, how VHHs are developed, and their growing use in diagnostics and therapy.

Immune checkpoint inhibitors transform oncology. Biointron explains PD-1, CTLA-4, and related therapies that unlock immune responses to fight cancer effectively.

Over four years have passed since the first SARS-CoV-2 outbreak, and scientific advancements have reshaped our understanding of immunity and virus dynamics.

Immune checkpoint blockade antibody therapy is an approach in cancer treatment that uses the body's immune system to target and destroy cancer cells. Immune checkpoints are regulatory pathways in immune cells that cancer cells exploit to evade detection. Key immune checkpoints include PD-1, PD-L1, and CTLA-4. By blocking these pathways, antibodies like pembrolizumab, nivolumab, and ipilimumab allow T-cells to recognize and attack cancer cells more effectively.

The Next-Gen Immuno-Oncology Conference 2024 in Boston featured advances in immunotherapy. Biointron shares insights driving future antibody-based treatments.

Infectious diseases like HIV and COVID-19 require novel therapies. Biointron shows how antibody drugs target pathogens to prevent infection and support recovery.

Afucosylated antibodies enhance ADCC for stronger therapies. Biointron highlights their mechanism and clinical applications improving efficacy across treatments.

Intravenous immunoglobulins (IVIGs) offer a versatile treatment modality for a variety of immune-mediated disorders. Originally used for antibody replacement therapy, their unexpected anti-inflammatory and immunomodulatory effects have allowed them to extend their use to

ADCs rely on diverse payloads. Biointron explores cytotoxic drugs and novel mechanisms that expand antibody-drug conjugate applications in oncology and beyond.

Multi-payload ADCs bring new strength to cancer therapy. Biointron explains how combining payloads boosts potency, reduces resistance, and improves patient outcomes.

Antibody drugs in ophthalmology represent a significant advancement in treating various eye diseases. These biologics target specific proteins involved in pathological processes, such as vascular endothelial growth factor (VEGF), which plays a key role in conditions like age-related macular degenera

Antibody-drug conjugates (ADCs) are made up of a monoclonal antibody linked to a cytotoxic drug (payload) through a stable chemical linker, enabling targeted delivery of the drug to specific cancer cells. The ideal ADC payload should have sufficient toxicity, low immunogenicity, high stability, and